Kyoto University · 의학
카즈타카 오바마 교수의 연구실은 간내 역행성 담도암(ICC)을 중심으로 한 분자 기전 규명과 진단·치료 표적 개발을 주요 연구 방향으로 삼고 있습니다. 특히 유전자 발현 프로파일링과 레이저 마이크로빔 미세분리 기술을 활용해 종양의 발달 메커니즘을 규명하고, PSF2와 같은 핵심 유전자를 통해 새로운 진단 마커와 치료 전략을 모색하고 있습니다. 이와 함께 담도암 및 대장암의 분자적 기전에 대한 통찰을 바탕으로 신약 개발과 정밀의료 전략 수립에도 기여하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
Early diagnosis of NOMI is possible using the above criteria and MDCT, and initiation of PGE1 treatment may increase survival in patients with NOMI.
Intrahepatic cholangiocarcinoma is a neoplasm arising in the liver, and its incidence is increasing in Japan as well as in Western countries. Prognosis of patients with this type of tumor remains unsatisfactory because no effective chemotherapeutic drugs are available, we have no sensitive tumor markers to detect this tumor in its early stage, and it is difficult to identify a high-risk group for the disease. To clarify the molecular mechanism of tumorigenesis and identify molecular targets for
Our findings may contribute to the better understanding of cholangiocarcinogenesis and open a new avenue to the development of novel therapeutic and/or diagnostic approach to this type of tumor.
To disclose molecular mechanisms of cholangiocarcinogenesis and to search for novel diagnostic markers and therapeutic targets for cholangiocarcinoma, we previously analyzed gene-expression profiles of 25 intrahepatic cholangiocarcinomas (ICCs) by means of a cDNA microarray re-presenting 27,648 genes. Among the genes frequently up-regulated in the cancer cells, we focused on PSF2 (partner of SLD five 2), a component of the GINS multiprotein complex that plays a crucial role in initiation of DNA
The findings reported here may offer new insight into colonic carcinogenesis and contribute to the development of new molecular strategies for treatment of human colorectal tumors.
